Compare Cart
  • Japanese
  • Korean
  • Traditional Chinese
  • Simplified Chinese
Cover Image
Market Research Report
Product code 
1070363

Cell Culture Market Size, Share & Trends Analysis By Product, By Application, By End User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
Published: | SPER Market Research Pvt. Ltd. | 223 Pages | Delivery time: 1-2 business days

Price

Back to Top
Cell Culture Market Size, Share & Trends Analysis By Product, By Application, By End User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
Published: April 13, 2022
SPER Market Research Pvt. Ltd.
Content info: 223 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents

Global cell culture market is projected to be worth USD 59.8 billion by 2030.

According to SPER Market Research, the cell culture market estimated to reach USD 59.8 billion by 2030 with a CAGR of 11.2%. Rising prevalence of infectious diseases and growing awareness for health has influenced the adoption of cell culture for vaccines, monoclonal antibodies and personalized medicine.

Impact of COVID-19 on the Cell Culture Market

COVID-19 pandemic has prompted the development of vaccines for immunization. Cell culture has played an important role in the manufacturing of the vaccines against SARS-CoV-2. Cell culture provides safe and continuous production of substrates for viral vaccines. This development has impacted to the growth of the cell culture market.

Scope of the report:

  • Market size available for years: 2019-2030
  • Base year considered: 2021
  • Forecast period: 2022-2030

Segments covered By Product, By Application, By End User

  • Geographies covered: North America, Europe, APAC, Latin America and the Middle East & Africa
  • Companies Covered: Adolf Kuhner AG, Agilent Technologies, Inc., ANGUS Chemical Company, Becton, Dickinson and Company, Biospherix Ltd., Caisson Laboratories Inc., Cellexus, Corning Incorporated, Danaher Corporation, Eppendorf AG, FUJIFILM Irvine Scientific, Inc., Getinge AB, HiMedia Laboratories, InvivoGen, Lonza Group AG, Meissner Filtration Products Inc., Merck KGaA, Miltenyi Biotec, Pan-Biotech GmbH, PromoCell GmbH, Sartorius AG, SeraCare Life Sciences Inc., Solida Biotech GmbH, STEMCELL Technologies Inc., Thermo Fisher Scientific Inc.

Driver: Rising awareness for cell-based vaccines

The prevalence of infectious diseases is rising globally. Cell culture technology can be used to prepare vaccines for various infectious diseases. The rising awareness for cell-based vaccines and their benefits is driving the growth of this market.

Restraints: High cost of research

Cell biology research consumes high quality reagents and equipment for providing accuracy in results. The regulatory approvals also insist the research to be done in highest quality to maintain standards. As a result, the research cost becomes very expensive which restraints the growth of this market.

Opportunity: Rising demand for 3D cell culture

The demand for 3D cell cultures is rising due to various advantages offered by 3D cell cultures as compared to 2D cell structures such as production of multi-dimensional cell cultures, better cell monitoring, greater stability and longer lifespan. Investors are also showing interest in this field which will significantly offer growth opportunities to this market.

Challenge: Generation of plastic waste

The cell culture relies on plastic consumables generating huge amount of plastic waste affecting the environment. The rising adoption of single-use bioprocessing systems is raising concerns related due to the disposal of solid waste materials. Recycling of such waste is not possible as it is composed of multiple plastic layers of polypropylene, nylon or polyethylene. The negative impact on the environment can be decreased in future with continuous research and development for eco-friendly equipment and techniques.

Cell Culture Market by Product:

Based on product, market has been segmented into Consumables (Sera, Media, and Reagents [Media (serum-free media, classical media & salts, stem cell culture media, specialty media, chemically defined media, and other media), Sera (fetal bovine sera (FBS), adult bovine sera (ABS), and other animal sera), Reagents (growth factors, supplements, buffers & chemicals, cell dissociation reagents, balanced salt solutions, attachment & matrix factors, antibiotics/antimycotics, contamination detection kits, cryoprotective agents, and other reagents)], Vessels [Roller/Roux Bottles, Cell Factory Systems/Cell Stacks, Multiwell Plates, Flasks, Petri Dishes], Accessories), Equipment (Supporting Equipment (filtration systems, cell counters, carbon dioxide incubators, centrifuges, autoclaves, microscopes, biosafety cabinets, and other supporting equipment such as pipetting aids, pipettes, cell inserts, cell scrapers, cell lifters, cell spreaders, pH meters, shakers, flow cytometers, and water baths), Bioreactors (conventional bioreactors, single-use bioreactors), Storage Equipment (Refrigerators & freezers, Cryostorage systems))

Cell Culture Market by Application:

Based on application, the market is segmented into Biopharmaceutical Production (Monoclonal antibodies, Vaccines production, Other therapeutic proteins), Diagnostics, Drug Screening & Development, Tissue Engineering & Regenerative Medicine (Cell and gene therapy, Other tissue engineering & regenerative medicine applications), Other Applications

Cell Culture Market by End User:

Based on end user, the market is segmented into Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Laboratories, Research & Academic Institutes, Other End Users

Pharmaceutical & Biotechnological companies have the largest share of this market by end user due to highest consumption of cell culture equipment & consumables and expansion of manufacturing units to increase the production capacity.

Cell Culture Market by Region:

North America owns the largest share of this market owing to rising regulatory approvals for cell culture-based vaccines, rapidly evolving biotechnology and pharmaceutical sector, rising incidence of cancer, supportive government initiatives, technological advancements and rising investments in cell-based research and development.

Product Code: BIOT2213

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary data
    • 2.1.2. Primary data
    • 2.1.3. SPER's internal database
    • 2.1.4. Premium insight from KOL's
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. COVID-19 Impact of the Cell Culture Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL analysis
    • 5.2.1. Political landscape
    • 5.2.2. Economic landscape
    • 5.2.3. Social landscape
    • 5.2.4. Technological landscape
    • 5.2.5. Environmental landscape
    • 5.2.6. Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of Buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat map analysis

6. Global Cell Culture Market, By Product, 2019-2030 (USD Million)

  • 6.1. Consumables
    • 6.1.1. Sera, Media, and Reagents
      • 6.1.1.1. Media (serum-free media, classical media & salts, stem cell culture media, specialty media, chemically defined media, and other media)
      • 6.1.1.2. Sera (fetal bovine sera (FBS), adult bovine sera (ABS), and other animal sera)
      • 6.1.1.3. Reagents (growth factors, supplements, buffers & chemicals, cell dissociation reagents, balanced salt solutions, attachment & matrix factors, antibiotics/antimycotics, contamination detection kits, cryoprotective agents, and other reagents)
    • 6.1.2. Vessels
      • 6.1.2.1. Roller/Roux Bottles
      • 6.1.2.2. Cell Factory Systems/Cell Stacks
      • 6.1.2.3. Multiwell Plates
      • 6.1.2.4. Flasks
      • 6.1.2.5. Petri Dishes
    • 6.1.3. Accessories
  • 6.2. Equipment
    • 6.2.1. Supporting Equipment (filtration systems, cell counters, carbon dioxide incubators, centrifuges, autoclaves, microscopes, biosafety cabinets, and other supporting equipment such as pipetting aids, pipettes, cell inserts, cell scrapers, cell lifters, cell spreaders, pH meters, shakers, flow cytometers, and water baths)
    • 6.2.2. Bioreactors (conventional bioreactors, single-use bioreactors)
    • 6.2.3. Storage Equipment (Refrigerators & freezers, Cryostorage systems)

7. Global Cell Culture Market, By Application, 2019-2030 (USD Million)

  • 7.1. Biopharmaceutical Production
    • 7.1.1. Monoclonal antibodies
    • 7.1.2. Vaccines production
    • 7.1.3. Other therapeutic proteins
  • 7.2. Diagnostics
  • 7.3. Drug Screening & Development
  • 7.4. Tissue Engineering & Regenerative Medicine
    • 7.4.1. Cell and gene therapy
    • 7.4.2. Other tissue engineering & regenerative medicine applications
  • 7.5. Other Applications

8. Global Cell Culture Market, By End User, 2019-2030 (USD Million)

  • 8.1. Pharmaceutical & Biotechnology Companies
  • 8.2. Hospitals & Diagnostic Laboratories
  • 8.3. Research & Academic Institutes
  • 8.4. Other End Users

9. Global Cell Culture Market, By Region, 2019-2030 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. Adolf Kuhner AG
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Agilent Technologies, Inc.
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. ANGUS Chemical Company
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. Becton, Dickinson and Company
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. Biospherix Ltd.
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6. Caisson Laboratories Inc.
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Cellexus
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. Corning Incorporated
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.9. Danaher Corporation
    • 10.9.1. Company details
    • 10.9.2. Financial outlook
    • 10.9.3. Product summary
    • 10.9.4. Recent developments
  • 10.10. Eppendorf AG
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments
  • 10.11. FUJIFILM Irvine Scientific, Inc.
    • 10.11.1. Company details
    • 10.11.2. Financial outlook
    • 10.11.3. Product summary
    • 10.11.4. Recent developments
  • 10.12. Getinge AB
    • 10.12.1. Company details
    • 10.12.2. Financial outlook
    • 10.12.3. Product summary
    • 10.12.4. Recent developments
  • 10.13. HiMedia Laboratories
    • 10.13.1. Company details
    • 10.13.2. Financial outlook
    • 10.13.3. Product summary
    • 10.13.4. Recent developments
  • 10.14. InvivoGen
    • 10.14.1. Company details
    • 10.14.2. Financial outlook
    • 10.14.3. Product summary
    • 10.14.4. Recent developments
  • 10.15. Lonza Group AG
    • 10.15.1. Company details
    • 10.15.2. Financial outlook
    • 10.15.3. Product summary
    • 10.15.4. Recent developments
  • 10.16. Meissner Filtration Products Inc.
    • 10.16.1. Company details
    • 10.16.2. Financial outlook
    • 10.16.3. Product summary
    • 10.16.4. Recent developments
  • 10.17. Merck KGaA
    • 10.17.1. Company details
    • 10.17.2. Financial outlook
    • 10.17.3. Product summary
    • 10.17.4. Recent developments
  • 10.18. Miltenyi Biotec
    • 10.18.1. Company details
    • 10.18.2. Financial outlook
    • 10.18.3. Product summary
    • 10.18.4. Recent developments
  • 10.19. Pan-Biotech GmbH
    • 10.19.1. Company details
    • 10.19.2. Financial outlook
    • 10.19.3. Product summary
    • 10.19.4. Recent developments
  • 10.20. PromoCell GmbH
    • 10.20.1. Company details
    • 10.20.2. Financial outlook
    • 10.20.3. Product summary
    • 10.20.4. Recent developments
  • 10.21. Sartorius AG
    • 10.21.1. Company details
    • 10.21.2. Financial outlook
    • 10.21.3. Product summary
    • 10.21.4. Recent developments
  • 10.22. SeraCare Life Sciences Inc.
    • 10.22.1. Company details
    • 10.22.2. Financial outlook
    • 10.22.3. Product summary
    • 10.22.4. Recent developments
  • 10.23. Solida Biotech GmbH
    • 10.23.1. Company details
    • 10.23.2. Financial outlook
    • 10.23.3. Product summary
    • 10.23.4. Recent developments
  • 10.24. STEMCELL Technologies Inc.
    • 10.24.1. Company details
    • 10.24.2. Financial outlook
    • 10.24.3. Product summary
    • 10.24.4. Recent developments
  • 10.25. Thermo Fisher Scientific Inc.
    • 10.25.1. Company details
    • 10.25.2. Financial outlook
    • 10.25.3. Product summary
    • 10.25.4. Recent developments